J Korean Diabetes.  2024 Sep;25(3):165-171. 10.4093/jkd.2024.25.3.165.

Management Strategies for Obese Diabetes

• Kim MS
• Lee SH

• KMID: 2559573
• DOI: http://doi.org/10.4093/jkd.2024.25.3.165

Abstract

In recent years, there has been a growing emphasis on the relationship between obesity and diabetes. An analysis of Korean data revealed that more than 75% of diabetic patients were overweight or obese, with two-thirds having abdominal obesity. Traditional treatment goals for diabetes have primarily focused on lowering blood glucose levels to prevent and treat microvascular and macrovascular complications, which is known as the glucocentric approach. However, with the recognition of the shared pathophysiology of insulin resistance in both diabetes and obesity, a weight-centric approach has emerged, particularly beneficial for patients in whom insulin resistance is a primary driver of type 2 diabetes. Of note, the overlap of various physiological aspects in diabetic patients necessitates a multicentric approach for effective type 2 diabetes management. Recent guidelines now recommend weight loss as a primary treatment goal alongside blood glucose control for overweight and obese diabetic patients, highlighting the significance of weight management in diabetes care. Medications such as glucagon-like peptide-1 (GLP-1) receptor agonist or dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist with weight-loss effects are recommended for this patient population. Ongoing research is exploring the potential of various gut hormone-based therapies, offering hope for effective weight management and improved diabetes outcomes in the growing population of obese diabetic individuals.

Keyword

Diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Incretins; Obesity

Reference

1.Bae JH., Han KD., Ko SH., Yang YS., Choi JH., Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022. 46:417–26.

2.Wilding JPH., Jacob S. Cardiovascular outcome trials in obesity: a review. Obes Rev. 2021. 22:e13112.

3.Lingvay I., Sumithran P., Cohen RV., le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022. 399:394–405.

4.American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care. 2024. 47(Suppl 1):S145–57.

5.Moon JS., Kang S., Choi JH., Lee KA., Moon JH., Chon S, et al. 2023 clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean Diabetes Association. Diabetes Metab J. 2024. 48:546–708.

6.Wing RR., Bolin P., Brancati FL., Bray GA., Clark JM., Coday M., Look AHEAD Research Group, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013. 369:145–54.

7.Lean MEJ., Leslie WS., Barnes AC., Brosnahan N., Thom G., McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019. 7:344–55.

8.Son JW., Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes Metab J. 2020. 44:802–18.

9.Gadde KM., Allison DB., Ryan DH., Peterson CA., Troupin B., Schwiers ML, et al. Effects of low-dose, controlled-re-lease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011. 377:1341–52.

10.Kirwan JP., Courcoulas AP., Cummings DE., Goldfine AB., Kashyap SR., Simonson DC, et al. Diabetes remission in the alliance of randomized trials of medicine versus met-abolic surgery in type 2 diabetes (ARMMS-T2D). Diabetes Care. 2022. 45:1574–83.

11.Aroda VR., Ahmann A., Cariou B., Chow F., Davies MJ., Jódar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019. 45:409–18.

12.Ji L., Dong X., Li Y., Li Y., Lim S., Liu M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sita-gliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021. 23:404–14.

13.Yabe D., Yamada Y., Kaku K., Nishida T., Sato T., Seino Y. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. J Diabetes Investig. 2022. 13:1161–74.

14.Marso SP., Bain SC., Consoli A., Eliaschewitz FG., Jódar E., Leiter LA., SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016. 375:1834–44.

15.Davies M., Færch L., Jeppesen OK., Pakseresht A., Pedersen SD., Perreault L., STEP 2 Study Group, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, dou-ble-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. 397:971–84.

16.Lincoff AM., Brown-Frandsen K., Colhoun HM., Deanfield J., Emerson SS., Esbjerg S., SELECT Trial Investigators, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. 389:2221–32.

17.Rosenstock J., Vázquez L., Del Prato S., Franco DR., Weer-akkody G., Dai B, et al. Achieving normoglycemia With tirzepatide: analysis of SURPASS 1-4 trials. Diabetes Care. 2023. 46:1986–92.

18.Frías JP., Davies MJ., Rosenstock J., Pérez Manghi FC., Fernández Landó L., Bergman BK., SURPASS-2 Investigators, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. 385:503–15.

19.Garvey WT., Frias JP., Jastreboff AM., le Roux CW., Sattar N., Aizenberg D., SURMOUNT-2 Investigators, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. 402:613–26.

20.Rodbard HW., Dougherty T., Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020. 26(16 Suppl):S335–43.

21.Frias JP., Hsia S., Eyde S., Liu R., Ma X., Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023. 402(10400):472–83.

22.Lau DCW., Erichsen L., Francisco AM., Satylganova A., le Roux CW., McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, place-bo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. 398:2160–72.

23.Enebo LB., Berthelsen KK., Kankam M., Lund MT., Rubino DM., Satylganova A, et al. Safety, tolerability, pharmacoki-netics, and pharmacodynamics of concomitant adminis-tration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. 397:1736–48.

24.Melson E., Ashraf U., Papamargaritis D., Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. doi: 10.1038/s41366-024-01473-y.[Epub ahead of print].